FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:35:218 | Switching the dose of mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European retrospective multicentre real-world study Edoardo Biancalana1, Irene Mattioli1, Emanuele Chiara2, Danilo Malandrino1, Maria Canfora1, Palmerini Miki1, Maria Paola Lisi1, Michela Gasparotto3, Paola Tomietto3, Maria Letizia Urban1, Giacomo Bagni1, Elena Silvestri1, Alessandra Bettiol3, Augusto Vaglio3, Giacomo Emmi2 | 1Department of Experimental and Clinical Medicine, University of Florence Firenze, Italy; 2Department of Medical, Surgery and Health Sciences, University of Trieste Trieste, Italy; 3Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Trieste, Italy; 4Department of Biomedical, Experimental and Clinical Sciences Mario Serio, University of Florence Firenze, Italy
48 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
59 -
PO:37:269 | Intensive therapeutic plasma exchange in life-threatening ANCA-associated vasculitis Davide Bertelle, Riccardo Bixio, Francesco Pollastri, Maurizio Rossini, Angelo Fassio, Alessandro Giollo | Unità di Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa
161 -
PO:24:060 | Evaluation of a Large Language Model Performance in Rating Cutaneous Manifestations of Dermatomyositis: A Comparison with Expert Assessors Gianmarco Roselli1, Marco Fornaro1, Swapnasha Panigrahi2, Sara Sabbagh3, Florenzo Iannone1, Vincenzo Venerito1, Latika Gupta4 | 1Università degli Studi di Bari, Unità di Reumatologia, DiMePRe-J Bari, Italy; 2University of Birmingham Birmingham, United Kingdom; 3Medical College of Wisconsin, Unit of Rheumatology, Department of Paediatrics Milwaukee, USA; 4University of Manchester, Manchester Academic Health Centre, Division of muscoloskeletal and deramatological sciences Manchester, United Kingdom
26 -
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Hn Harris4, Ciara O'Shea5, Roger A. Levy6, Andrea Doria7 | 1Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; 2Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; 3Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; 4GSK, Immunologia Biostatistica London, UK; 5GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; 6GSK, Global Medical Affairs Collegeville, PA, USA; 7Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy
171 -
CO:09:3 | Effectiveness and safety of nintedanib in autoimmune systemic diseases: real life data from an Italian multicentre study (Island group) of the Italian Society of Rheumatology Corrado Campochiaro1, Paola Conigliaro2, Gianluca Sambataro3, Marco Matucci-Cerinic1, Marco Sebastiani4, Gianluca Bajocchi5, Angelo Fassio6, Elena Treppo7, Elisabetta Zanatta8, Elena Bartolini9, Francesco Ferro10, Chiara Bazzini11, Nicoletta Del Papa12, Gemma Lepri13, Andrea Lo Monaco14, Marta Favero15, Annamaria Iuliano16, Francesca Li Gobbi17, Maria Sole Chimenti2, Giuseppe Muscato18, Giacomo De Luca1, Francesca Cozzini4, Lucia Dardani5, Francesco Pollastri6, Alessandro Gattron7, Beatrice Moccaldi8, Caterina Antonini9, Gaetano La Rocca10, Ilaria Cavazzana11, Andreina Manfredi5|19. | 1IRCCS San Raffaele Hospital, Vita-Salute San Raffaele, Milano; 2U.O.C. Reumatologia Dipartimento di Medicina dei Sistemi Università di Roma-Tor Vergata, Roma; 3Università Kore, Enna; 4University of Parma, Azienda Ospedaliera di Piacenza; 5UOC Reumatologia, AUSL IRCCS Reggio Emilia; 6UOC Reumatologia Università degli Studi di Verona; 7Dipartimento di Medicina, Clinica di Reumatologia, Università degli Studi di Udine; 8UOC Reumatologia, Dipartimento di Medicina DIMED, Azienda Ospedale Università di Padova; 9SC Interaziendale di Reumatologia, Dipartimento di Medicina e Chirurgia, Università di Perugia, Azienda Integrata Università; 10Dipartimento di Medicina Clinica e Sperimentale UO Reumatologia-Universitaria AOU Pisa; 11U.O. Reumatologia e Immunologia Clinica ASST Spedali Civili di Brescia; 12Clinica Reumatologica, Milano; 13S.O.D. di Reumatologia AOU Careggi, Firenze; 14UOC Reumatologia Azienda Ospedaliero-Universitaria Sant'Anna, Ferrara; 15Internal Medicine I, Department of Medicine, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso; 16UOC Reumatologia, AO San Camillo Forlanini, Roma; 17Rheumatology Unit, S.Giovanni di Dio Hospital, Firenze; 18Department of Clinical and Experimental Medicine, Regional Referral Center for Rare Lung Disease, Policlinico, Catania; 19Università degli Studi di Modena e Reggio Emilia, Italy
157 -
PO:18:264 | Anifrolumab in Systemic Lupus Erythematosus: Bridging Clinical Trial Data with Real-World Evidence Giulia Cassone2, Filippo Santoro1, Caterina Vacchi2, Dilia Giuggioli2, Chiara Cabassi1 | 1UOC Reumatologia, AOU Policlinico di Modena, Università degli studi di Modena e Reggio Emilia Modena e Reggio Emilia, Italy; 2UOC Reumatologia, AOU Policlinico di Modena Modena, Italy
90 -
PO:26:092 | Early antiproteinuric effect of voclosporine in patients with lupus nephritis in real life setting: preliminary results from the VoRLiSS (Voclosporine in Real Life Setting Study) Aurora Di Gregorio1, Marta Calatroni2, Marco Allinovi3, Alessandra Bortoluzzi4, Giorgio Buscetta5, Rossella De Angelis6, Ginevra De Marchi7, Giacomo Emmi8, Pasquale Esposito9, Paride Fenaroli10, Micaela Fredi11, Giovanni Orsolini12, Giulia Pazzola13, Domenico Santoro14, Andrea Doria1, Gabriella Moroni2, Luca Iaccarino1 | 1Azienda Ospedaliera Universitaria Padova, Italy; 2Ospedale IRCCS Humanitas Milano, Italy; 3Azienda Ospedaliero Universitaria Careggi Firenze, Italy; 4Azienda Ospedaliero Universitaria di Ferrara, Italy; 5Policlinico Universitario Paolo Giaccone Palermo, Italy; 6Università Politecnica delle Marche Ancona, Italy; 7Università di Udine, Italy; 8Università di Trieste, Italy; 9Università di Genova, Italy; 10Unità di Nefrologia AUSL IRCCS di Reggio Emilia, Italy; 11Università di Brescia, Italy; 12Università di Verona Verona, Italy; 13Università di Reggio Emilia, Italy; 14Azienda Ospedaliera Universitaria G. Martino di Messina, Italy
49 -
PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France
43 -
PO:02:022 | Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3|4|5, Joerg Ermann6, Alexander Marten7, Ute Massow7, George Stojan8, Vanessa Taieb9, Diana Voiniciuc10, Astrid Van Tubergen11, Victoria Navarro-Compán12, Simone Angioni13, Xenofon Baraliakos14 | 1Charité-Universitätsmedizin Berlin; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 3Weill Cornell Medical Center New York, USA; 4New York Presbyterian Hospital New York, USA; 5Hospital for Special Surgery New York, USA; 6Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School Boston, USA; 7UCB Monheim am Rhein Germany; 8UCB Atlanta, USA; 9UCB Colombes, France; 10UCB Slough, United Kingdom; 11Department of Medicine, Division of Rheumatology, Maastricht University Medical Center Maastricht, The Netherlands; 12Department of Rheumatology, La Paz University Hospital, IdiPaz Madrid, Spain; 13UCB Milan, Italy; 14Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
32 -
PO:37:258 | Neutrophil and eosinophil extracellular traps in eosinophilic granulomatosis with polyangiitis: phenotype-based characterization and response to mepolizumab Michele Moretti1, Francesco Ferro2, Francesco Pisani1, Elisa Ferrigno1, Gaetano La Rocca1, Federica Di Cianni3, Rosaria Talarico2, Marta Mosca1, Chiara Baldini1, Ilaria Puxeddu1. | 1University of Pisa - Department of Clinical and Experimental Medicine, Pisa, Italy; 2Azienda Ospedaliero Universitaria Pisana - Rheumatology Unit, Pisa, Italy; 3University of Siena, Siena, Italy.
165 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
71 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
327
1 - 21 of 21 items
